Pursuing better treatments to help patients feel better, longer.

Advancing palazestrant for breast cancer

Palazestrant (OP-1250), our lead candidate, is a once-daily oral medicine with best-in-class potential for metastatic breast cancer.

Current clinical trials

OPERA-01 Phase 3 study is for people with advanced and/or metastatic ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitors and endocrine therapy.

Bring your passion, join our team and make your mark.

Life at Olema

We are fostering a culture of collaboration, understanding, and inclusion that celebrates diverse backgrounds and expertise. Looking to make a difference in oncology? Explore our job opportunities.

Olema's latest news and recent events.

January 3, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 2, 2025 Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 10, 2024 Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
December 9, 2024 Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor